Merck reaches deal to expand HIV drug access via ADAP programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV
June 29, 2026 6:45 AM EDTAgreement will help state ADAP programs provide access to IDVYNSO (doravirine/islatravir) for eligible individuals
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced an agreement with the ADAP Crisis Task Force (ACTF) to help state AIDS Drug Assistance Programs (ADAPs) provide access to the companys new once-daily HIV treatment, IDVYNSO (doravirine/islatravir). In 2024, state ADAPs supported more than 250,000 people with HIV in the United States.
IDVYNSO was approved by the U.S. Food and Drug... More
